AbbVie agreed on June 22, 2026 to acquire Apogee Therapeutics for $135.11 per share in cash — a total enterprise value of $10.9 billion — its largest buyout in more than five years, according to CNBC and AbbVie's own announcement.

The offer price carries a 49.49% premium to Apogee's closing price on Thursday, June 19. Apogee's stock surged 47% to $132.65 on the announcement — roughly three percentage points short of the deal price, which is a typical spread reflecting execution and regulatory risk, not deal skepticism. The gap between the trading price and $135.11 is the arb community's implicit probability-weighted discount for deal failure.

The strategic rationale centers on zumilokibart, Apogee's lead asset: an experimental monoclonal antibody targeting the IL-13 receptor alpha-1, developed for atopic dermatitis and other inflammatory conditions, per Investing.com. For AbbVie, this is portfolio defense with a specific shape. Skyrizi and Rinvoq have absorbed much of the Humira revenue erosion since biosimilar entry accelerated in 2023, but AbbVie's immunology franchise still needs next-generation assets with differentiated mechanisms. Zumilokibart — if it clears late-stage trials — could compete in the atopic derm space where Dupixent (dupilumab) currently commands a dominant position. AbbVie is paying for clinical optionality; it is not paying for approved cashflows.

That pricing reality is embedded in the earnings impact. AbbVie disclosed it expects the deal to dilute adjusted EPS by roughly 14%, per Barron's. For a large-cap pharma company carrying meaningful leverage from prior acquisitions, absorbing double-digit EPS dilution is a deliberate choice to buy duration — time and pipeline depth — rather than near-term accretion. That dilution figure will dominate the Q3 earnings narrative and is already the central variable for sell-side models repricing AbbVie's 2027 and 2028 estimates.

At $10.9 billion all-cash, the deal is AbbVie writing a check, not structuring a creative exchange. Cash acquisitions of this scale require confidence in the balance sheet's ability to absorb the outlay while maintaining dividend coverage and investment-grade credit metrics. AbbVie generated roughly $22 billion in operating cash flow in 2024, which provides the headroom — but the market will watch leverage ratios closely through the integration period.

The broader competitive context matters here. The atopic dermatitis market is large and still growing, but it is not untested territory. Sanofi and Regeneron's Dupixent has set a high clinical bar, and new entrants — including Lilly's lebrikizumab and AstraZeneca's tezepelumab in adjacent indications — mean AbbVie needs differentiation, not just efficacy parity. Whether zumilokibart's mechanism delivers a meaningfully distinct profile versus IL-4/IL-13 dual blockade remains the clinical question the acquisition does not answer. AbbVie is acquiring the right to find out, at scale.

For deal-watchers, the premium — just under 50% — is aggressive but consistent with contested pre-clinical and early-clinical stage assets in high-demand therapeutic areas. Reuters had reported AbbVie was nearing an approximately $11 billion deal as early as June 19, per Reuters, meaning the structure was largely locked before announcement. The absence of surprise in the final terms suggests a clean, bilateral negotiation rather than an auction that drove the price above initial expectations.

AbbVie has not disclosed a closing timeline, but all-cash transactions of this type typically clear within six to nine months, subject to customary antitrust review. Given both companies operate primarily in the US and Apogee has no approved products generating competitive market share, substantive regulatory obstruction is unlikely — though not impossible given the current FTC's continued scrutiny of large pharma consolidation. The deal terms, if executed, will fold Apogee entirely into AbbVie's immunology unit.